JP5591705B2 - 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用 - Google Patents

抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用 Download PDF

Info

Publication number
JP5591705B2
JP5591705B2 JP2010527303A JP2010527303A JP5591705B2 JP 5591705 B2 JP5591705 B2 JP 5591705B2 JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010527303 A JP2010527303 A JP 2010527303A JP 5591705 B2 JP5591705 B2 JP 5591705B2
Authority
JP
Japan
Prior art keywords
antigen
amphiphilic compound
vaccine composition
hydrophobic carrier
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010527303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540570A (ja
JP2010540570A5 (cg-RX-API-DMAC7.html
Inventor
マンスール，マルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovaccine Technologies Inc
Original Assignee
Immunovaccine Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovaccine Technologies Inc filed Critical Immunovaccine Technologies Inc
Publication of JP2010540570A publication Critical patent/JP2010540570A/ja
Publication of JP2010540570A5 publication Critical patent/JP2010540570A5/ja
Application granted granted Critical
Publication of JP5591705B2 publication Critical patent/JP5591705B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
JP2010527303A 2007-10-03 2008-10-02 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用 Expired - Fee Related JP5591705B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97719707P 2007-10-03 2007-10-03
US60/977,197 2007-10-03
PCT/CA2008/001747 WO2009043165A1 (en) 2007-10-03 2008-10-02 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof

Publications (3)

Publication Number Publication Date
JP2010540570A JP2010540570A (ja) 2010-12-24
JP2010540570A5 JP2010540570A5 (cg-RX-API-DMAC7.html) 2011-11-10
JP5591705B2 true JP5591705B2 (ja) 2014-09-17

Family

ID=40525804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527303A Expired - Fee Related JP5591705B2 (ja) 2007-10-03 2008-10-02 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用

Country Status (7)

Country Link
EP (1) EP2195022A4 (cg-RX-API-DMAC7.html)
JP (1) JP5591705B2 (cg-RX-API-DMAC7.html)
CN (1) CN101815529B (cg-RX-API-DMAC7.html)
AU (1) AU2008307042B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817484B1 (cg-RX-API-DMAC7.html)
CA (1) CA2700828C (cg-RX-API-DMAC7.html)
WO (1) WO2009043165A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
WO2009146523A1 (en) 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
IN2014CN02581A (cg-RX-API-DMAC7.html) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
WO2014153636A1 (en) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
CN105044328A (zh) * 2015-05-28 2015-11-11 首都医科大学附属北京佑安医院 Elispot预包被培养板及其制备方法
JP6989134B2 (ja) * 2015-11-18 2022-01-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
CA3022924A1 (en) * 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
CA3038155A1 (en) 2016-09-27 2018-04-05 Immunovaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
IL302880A (en) 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
EP4294431A4 (en) * 2021-02-16 2025-05-07 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles based on amphiphilic peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI944052A7 (fi) * 1992-03-03 1994-09-02 Daiichi Seiyaku Co Oraalinen rokote
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
AU8053898A (en) * 1997-05-28 1998-12-30 Jenner Biotherapies, Inc. Immunogenic compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP4164361B2 (ja) * 2000-11-07 2008-10-15 イムノワクチン テクノロジーズ インコーポレーテッド 増強した免疫応答を有するワクチン、およびその調製方法
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy

Also Published As

Publication number Publication date
WO2009043165A1 (en) 2009-04-09
CN101815529A (zh) 2010-08-25
BRPI0817484B1 (pt) 2021-08-17
JP2010540570A (ja) 2010-12-24
AU2008307042B2 (en) 2014-01-30
CN101815529B (zh) 2016-03-09
CA2700828A1 (en) 2009-04-09
AU2008307042A1 (en) 2009-04-09
CA2700828C (en) 2017-01-24
BRPI0817484A2 (pt) 2015-03-24
EP2195022A4 (en) 2012-08-01
EP2195022A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
JP5591705B2 (ja) 抗原、両親媒性化合物及び疎水性担体を含有する組成物、並びにその使用
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US11717563B2 (en) Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US20220001010A1 (en) Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
Shahiwala et al. Nanocarriers for systemic and mucosal vaccine delivery
US20180289801A1 (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer
JP2014528955A5 (cg-RX-API-DMAC7.html)
US20180162913A1 (en) Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
US20100209452A1 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
HK1155642B (en) Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140730

R150 Certificate of patent or registration of utility model

Ref document number: 5591705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees